Charles River Laboratories International Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Charles River Laboratories International Inc 公司

Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.

Charles River Laboratories International Inc簡介



公司代碼CRL

公司名稱Charles River Laboratories International Inc

上市日期Jun 23, 2000

CEOFoster (James C)

員工數量18600

證券類型Ordinary Share

年結日Jun 23

公司地址251 Ballardvale St

城市WILMINGTON

上市交易所NASDAQ OMX NASDAQ Basic NYSE

國家United States of America

郵編01887

電話17812226000

網址https://www.criver.com/

公司代碼CRL

上市日期Jun 23, 2000

CEOFoster (James C)

Charles River Laboratories International Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. James C. Foster

Chairman of the Board, President, Chief Executive Officer

309.13K

+5.43%

Ms. Birgit Girshick

Chief Operating Officer, Corporate Executive Vice President

64.16K

+10.04%

Ms. Victoria L. (Vicky) Creamer

Corporate Executive Vice President, Chief People Officer

21.60K

+17.18%

Ms. Shannon M. Parisotto

Corporate Executive Vice President - Discovery and Safety Assessment Management

16.05K

+19.74%

Mr. Joseph W. LaPlume

Corporate Executive Vice President - Corporate Development and Strategy

15.81K

+0.16%

Ms. Virginia M. (Gina) Wilson, CPA

Independent Director

4.91K

+19.26%

Dr. Nancy C. Andrews, M.D., Ph.D.

Independent Director

3.96K

+23.86%

Ms. Reshema Kemps-Polanco

Independent Director

2.59K

+60.85%

Dr. Craig B. Thompson, M.D.

Independent Director

2.41K

+39.20%

Mr. Abraham N. (Abe) Ceesay

Independent Director

946.00

--

名稱

名稱/職務

職務

持股

持股變動

Mr. James C. Foster

Chairman of the Board, President, Chief Executive Officer

309.13K

+5.43%

Ms. Birgit Girshick

Chief Operating Officer, Corporate Executive Vice President

64.16K

+10.04%

Ms. Victoria L. (Vicky) Creamer

Corporate Executive Vice President, Chief People Officer

21.60K

+17.18%

Ms. Shannon M. Parisotto

Corporate Executive Vice President - Discovery and Safety Assessment Management

16.05K

+19.74%

Mr. Joseph W. LaPlume

Corporate Executive Vice President - Corporate Development and Strategy

15.81K

+0.16%

Ms. Virginia M. (Gina) Wilson, CPA

Independent Director

4.91K

+19.26%

收入明細

單位: USD更新時間: 6 小時前

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

業務USD

名稱

營收

佔比

DSA

2.40B

59.84%

RMS

846.08M

21.07%

Manufacturing

766.41M

19.09%

地區USD

名稱

營收

佔比

United States

2.14B

53.34%

Europe

1.10B

27.46%

Canada

501.02M

12.48%

Asia Pacific (Region)

205.02M

5.11%

Other

64.86M

1.62%

業務

地區

業務USD

名稱

營收

佔比

DSA

2.40B

59.84%

RMS

846.08M

21.07%

Manufacturing

766.41M

19.09%

股東統計

更新時間: 3月28日週六

持股股東

股東類型

持股股東

佔比

The Vanguard Group, Inc.

11.93%

BlackRock Institutional Trust Company, N.A.

5.85%

Allspring Global Investments, LLC

4.05%

State Street Investment Management (US)

3.80%

Invesco Advisers, Inc.

3.61%

其他

70.76%

持股股東

佔比

The Vanguard Group, Inc.

11.93%

BlackRock Institutional Trust Company, N.A.

5.85%

Allspring Global Investments, LLC

4.05%

State Street Investment Management (US)

3.80%

Invesco Advisers, Inc.

3.61%

其他

70.76%

股東類型

持股股東

佔比

Investment Advisor/Hedge Fund

48.67%

Investment Advisor

47.43%

Hedge Fund

9.25%

Research Firm

2.28%

Pension Fund

1.46%

Individual Investor

1.13%

Sovereign Wealth Fund

0.99%

Bank and Trust

0.71%

Family Office

0.09%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

1367

52.25M

129.09%

+28.56K

2025Q3

1413

52.22M

129.54%

+64.86K

2025Q2

1411

52.12M

127.74%

-2.86M

2025Q1

1414

54.69M

123.53%

-5.98M

2024Q4

1410

54.25M

114.75%

+1.17M

2024Q3

1372

53.38M

114.53%

-33.66K

2024Q2

1378

53.46M

111.45%

+347.48K

2024Q1

1371

53.18M

111.09%

-4.05M

2023Q4

1405

52.96M

112.24%

-202.82K

2023Q3

1421

52.99M

111.08%

+631.82K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

5.88M

11.93%

+47.43K

+0.81%

Dec 31, 2025

BlackRock Institutional Trust Company, N.A.

2.88M

5.85%

+56.48K

+2.00%

Dec 31, 2025

Allspring Global Investments, LLC

2.00M

4.05%

-182.34K

-8.37%

Dec 31, 2025

State Street Investment Management (US)

1.87M

3.8%

+40.53K

+2.21%

Dec 31, 2025

Invesco Advisers, Inc.

1.78M

3.61%

+1.63M

+1113.97%

Dec 31, 2025

Wellington Management Company, LLP

1.75M

3.55%

-1.44M

-45.17%

Dec 31, 2025

Harris Associates L.P.

1.68M

3.41%

+204.52K

+13.88%

Dec 31, 2025

Fidelity Management & Research Company LLC

1.55M

3.15%

+1.15M

+293.11%

Dec 31, 2025

Dimensional Fund Advisors, L.P.

1.44M

2.93%

+311.32K

+27.53%

Dec 31, 2025

Ariel Investments, LLC

1.43M

2.9%

-62.33K

-4.18%

Dec 31, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Invesco S&P 500 Equal Weight Health Care ETF

1.92%

Schwab Ariel Opportunities ETF

1.82%

iShares Health Innovation Active ETF

1.74%

First Trust NASDAQ Pharmaceuticals ETF

1.71%

ROBO Global Healthcare Technology & Innovation ETF

1.69%

VanEck Biotech ETF

1.44%

Franklin Genomic Advancements ETF

1.42%

WisdomTree US Value Fund

1.15%

Invesco S&P 500 High Beta ETF

1.14%

Pacer Lunt Large Cap Alternator ETF

0.97%

Invesco S&P 500 Equal Weight Health Care ETF

佔比1.92%

Schwab Ariel Opportunities ETF

佔比1.82%

iShares Health Innovation Active ETF

佔比1.74%

First Trust NASDAQ Pharmaceuticals ETF

佔比1.71%

ROBO Global Healthcare Technology & Innovation ETF

佔比1.69%

VanEck Biotech ETF

佔比1.44%

Franklin Genomic Advancements ETF

佔比1.42%

WisdomTree US Value Fund

佔比1.15%

Invesco S&P 500 High Beta ETF

佔比1.14%

Pacer Lunt Large Cap Alternator ETF

佔比0.97%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

暫無數據

公告日期

除權除息日

類型

比率

暫無數據